Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dai Chihara

Blood

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Blood|July 6, 2026
The Chaos of Choice in Large B-cell Lymphoma: A Call to Harmonize First-line Trial DesignDai Chihara, Jason R Westin
Blood|April 6, 2021
The bidirectional increased risk of B-cell lymphoma and T-cell lymphomaDai Chihara, Graça M Dores, Christopher R Flowers, et al.
Blood|June 20, 2023
Real-world experience of CAR T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphomaDai Chihara, Laura Liao, Joseph Tkacz, et al.
Blood|February 7, 2012
Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in JapanTakashi Tokunaga, Kazuyuki Shimada, Kazuhito Yamamoto, et al.
Blood|March 23, 2021
Phase 2 study of ibrutinib in classic and variant hairy cell leukemiaKerry A Rogers, Leslie A Andritsos, Lai Wei, et al.
Blood|April 14, 2026
Diagnosis-to-Treatment Interval Is Associated With Outcomes in Follicular Lymphoma Treated with ImmunochemotherapyProkop Vodička, Tarec C El-Galaly, Vit Prochazka, et al.
Blood|October 23, 2024
Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapyRishika Prasad, Abdur Rehman, Lubna Rehman, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Blood|July 6, 2026
The Chaos of Choice in Large B-cell Lymphoma: A Call to Harmonize First-line Trial DesignDai Chihara, Jason R Westin
Blood|April 6, 2021
The bidirectional increased risk of B-cell lymphoma and T-cell lymphomaDai Chihara, Graça M Dores, Christopher R Flowers, et al.
Blood|June 20, 2023
Real-world experience of CAR T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphomaDai Chihara, Laura Liao, Joseph Tkacz, et al.
Blood|February 7, 2012
Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in JapanTakashi Tokunaga, Kazuyuki Shimada, Kazuhito Yamamoto, et al.
Blood|March 23, 2021
Phase 2 study of ibrutinib in classic and variant hairy cell leukemiaKerry A Rogers, Leslie A Andritsos, Lai Wei, et al.
Blood|April 14, 2026
Diagnosis-to-Treatment Interval Is Associated With Outcomes in Follicular Lymphoma Treated with ImmunochemotherapyProkop Vodička, Tarec C El-Galaly, Vit Prochazka, et al.
Blood|October 23, 2024
Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapyRishika Prasad, Abdur Rehman, Lubna Rehman, et al.
Pageof 1